Navigation Links
EntreMed Reports Third Quarter 2008 Financial Results
Date:11/6/2008

tiated in 2006 and 2007. We expect research and development expenses to trend down in the fourth quarter and into 2009 as we collect clinical data and evaluate each program to determine future clinical direction. At the end of the quarter we reported $27.9 million in cash and short-term investments, which together with anticipated royalty inflows, we believe will fund planned operations for at least the next 12 months."

James S. Burns, EntreMed President and Chief Executive Officer, commented, "We are actively pursuing partners for ENMD-2076 and Panzem(R) RA while continuing our clinical oncology programs, including the Phase 1b dose-escalation study in solid tumors for ENMD-2076. The outcome of our partnering initiatives and anticipated clinical progress will guide our priorities through year-end and into 2009. While we are reducing overall expenses, our clinical trials remain on schedule. We anticipate the presentation of clinical and preclinical data for MKC-1, ENMD-2076 and ENMD-1198 over the next several quarters."

Mr. Burns will present a Company overview at the Rodman & Renshaw 10th Annual Healthcare Conference, which will serve as the Company's third quarter 2008 update. Mr. Burns' presentation is scheduled for 2:25 p.m. (ET) on Tuesday, November 11, 2008 and will be web cast. To access the live presentation, visit the Company's web site at http://www.entremed.com. An archive of the presentation will be available on the web site for approximately 90 days.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway, is currently in multiple Phase 2 clinical trials for cancer. ENMD-2076, a selective angiogenic kinase inhibitor, and ENMD-1198, a novel antimitotic agent are in Phase 1 studies in advanced canc
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
2. EntreMed to Present at BioPartnering Europe Conference
3. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
4. EntreMed Reports Second Quarter 2008 Financial Results
5. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
6. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
7. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
8. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
9. EntreMed Receives Nasdaq Deficiency Notice
10. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
11. EntreMed Announces 2008 Corporate and Clinical Program Priorities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... ANTONIO , 23 de julio de 2014 ... (ADBI o la Compañía) ha anunciado hoy una ... Akron (ABIA o el Instituto), para ... ADBI, un dispositivo de terapia de señal bioeléctrica ... El Instituto, que tiene una importante ...
(Date:7/23/2014)... July 23, 2014 /PRNewswire/ - BioAmber Inc. (NYSE: ... producing sustainable chemicals, today announced that the underwriters of ... option to purchase an additional 420,000 shares of ... $12.00 per share, less underwriting discounts and commissions, ... offering of 2,800,000 shares of common stock, bringing ...
(Date:7/23/2014)... July 23, 2014  Sofinnova Ventures, a ... the closing of Sofinnova Venture Partners IX, L.P. at ... of the initial fund target of $425 million. ... biotechnology companies. Consistent with recent funds, SVP IX will ... clinical programs, along with select investments in earlier stage ...
(Date:7/23/2014)... 23, 2014 a2z Inc. announces that ... App, AACC Pathfinder, in its 2014 Annual Meeting ... meeting is planned for July 29-31, 2014 in Chicago, ... be to connect with global leaders in clinical chemistry, ... other areas of breaking science in laboratory medicine. , ...
Breaking Biology Technology:ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 2ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 3ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 4ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 5ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 6BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 3Sofinnova Raises $500 Million Biotech Venture Fund 2AACC Enhances Attendee Experience at Its 2014 Annual Meeting & Clinical Lab Expo with a2z-Powered ChirpE Photo Booth and Mobile App 2AACC Enhances Attendee Experience at Its 2014 Annual Meeting & Clinical Lab Expo with a2z-Powered ChirpE Photo Booth and Mobile App 3
... The single-atom thick material graphene maintains its high ... step to advancing the material from a laboratory phenomenon ... devices, researchers report in the April 9 issue of ... engineers and theoretical physicists from the University of Texas ...
... Mechanical Engineering at Stevens Institute of Technology was named ... (YIP) award by the Office of Naval Research (ONR). ... exceptional promise for creative study. "We are proud ... said ONR,s Director of Research Dr. Michael Kassner. "Through ...
... ... Regulatory Submissions , ... Rockville, MD (Vocus) April 8, 2010 -- Bringing its popular interactive workshop to Europe ... eCTD Submissions in Brussels, 5–7 May. This introductory workshop guides participants on how to ...
Cached Biology Technology:With support, graphene still a superior thermal conductor 2Dr. Chang-Hwan Choi honored with prestigious Young Investigator Award 2Dr. Chang-Hwan Choi honored with prestigious Young Investigator Award 3RAPS to Host eCTD Submissions Workshop in Brussels 2RAPS to Host eCTD Submissions Workshop in Brussels 3
(Date:7/23/2014)... the world have no access to clean drinking water. ... people die from water-related diseases every year. ETH student ... contribution to solving this problem. Working with researchers from ... Functional Materials Laboratory, the 23-year-old spent a year researching ... makes our DrinkPure filter unique is that you can ...
(Date:7/23/2014)... personalized cancer medicine, (the WIN consortium), recently announced that ... University will be one of its six new ... in the Tri-State Area. The goal of WIN is ... the patient by forging collaborations between partners in academia, ... WIN consortium means Jefferson cancer patients will have access ...
(Date:7/23/2014)... potential for clinical use of induced pluripotent stem ... previously been hindered by the risk of dysregulated ... ability to use etoposide treatment to halt teratoma ... disease, specifically acute myocardial infarction, is demonstrated in ... , a peer-reviewed journal from Mary Ann Liebert, ...
Breaking Biology News(10 mins):ETH student develops filter for clean water around the world 2New partnership brings more personalized cancer treatment to Philadelphia 2
... research professor and professor emeritus at The University of ... the American Academy of Arts & Sciences (AAAS), along ... Earl Jones, U.S. Secretary of Defense Robert Gates and ... scientist who translates his discoveries into technology that helps ...
... New York Sea Grant (NYSG) announces the release of ... Populations in South Shore Bays of Long Island, NY, ... of five research projects funded through NYSG,s Hard Clam ... NOAA National Marine Fisheries Service, South Shore Estuary Reserve, ...
... In Maine, government scientists have figured out how to measure ... and the sun - all the while saving money, energy, ... this energy-efficient ingenuity was the need to help the National ... spring snowmelt. The problem was this: While the USGS ...
Cached Biology News:University of Texas at Austin engineer elected to American Academy of Arts and Sciences 2University of Texas at Austin engineer elected to American Academy of Arts and Sciences 3Sea Grant report synthesizes recent research on New York's clams 2Measuring snow with a bucket, a windmill, and the sun? 2
Anti-G-alpha-i 1 G-Protein Host: mouse monoclonal Species Reactivity: human, mouse, rat Applications: WB Storage: 4C...
oligophrenin-1 (H-100)...
Mouse monoclonal [DAPK-55] to DAP Kinase 1 ( Abpromise for all tested applications). entrezGeneID: 1612 SwissProtID: P53355...
Mouse monoclonal [1.T.4] to WAVE 1 ( Abpromise for all tested applications). Antigen: His6 fusion protein corresponding to full-length rat WAVE1. Entrez Gene ID: 8936...
Biology Products: